The value of $^{18}$F-NaF PET/CT in the diagnosis of bone metastases in patients with nasopharyngeal carcinoma using visual and quantitative analyses

Dong Wang$^{1*}$, HaiWen Li$^{2†}$, ChengMao Guo$^1$, Shisang Huang$^1$, XuFeng Guo$^1$ and JingXing Xiao$^1$

$^1$Department of Nuclear Medicine (PET-CT center), Affiliated Hospital of Guangdong Medical University, ZhangJiang, China, $^2$Cancer Center, Affiliated Hospital of Guangdong Medical University, ZhangJiang, China

To assess the diagnostic value of $^{18}$F-NaF PET/CT in diagnosing bone metastases in patients with nasopharyngeal carcinoma (NPC) using visual and quantitative analyses. 164 patients with NPC who underwent $^{18}$F-NaF PET/CT between 2017 and 2021 were included. The sensitivity, specificity, and accuracy were calculated. All bone lesions were divided into metastatic bone lesion group and benign lesion group; the benign lesion group was further subdivided into benign lesion without osteophyte and fracture group (CT images showing no osteophyte, no fracture), and benign lesion with osteophyte and fracture group (CT images showing typical osteophytes and fractures), the differences in maximum standardized uptake value (SUVmax) were compared between every two groups, and the diagnostic cut-off values were derived from receiver operating characteristic curves (ROC). Quantitative data were expressed as mean ± SD, multiple continuous variables were compared using one-way analysis of variance (ANOVA), and multiple comparisons among more than two groups were made using the Bonferroni method. The sensitivity, specificity, and overall accuracy of $^{18}$F-NaF PET/CT for the diagnosis of bone metastases in NPC were 97.1%, 94.6%, and 95.1% based on the patient level and 99.5%, 91.5%, and 96.4% based on the lesion level, respectively. The SUVmax was significantly different between the metastatic bone lesion group and the benign lesion without osteophyte and fracture group ($p < 0.05$); the area under the curve was 0.865, the threshold was 12.5, the sensitivity was 0.912, and the specificity was 0.656. Visual analysis of $^{18}$F-NaF PET/CT has high sensitivity and specificity for diagnosing bone metastases in NPC. After excluding osteophytes and fracture lesions based on CT findings, using SUVmax $\geq 12.5$ as the threshold can be an important reference for the differential diagnosis of bone metastases and benign bone lesions in patients with NPC.
Introduction

The incidence of nasopharyngeal carcinoma (NPC) geographically varies, and its highest incidence was reported in southern China. The risk of distant metastasis is even higher in patients with T4 and N3 stages, and the rate of distant metastasis is as high as 45–60% in patients who died. The more frequent sites of distant metastasis were bones, lungs, and non-cervical lymph nodes (Shen L. J et al., 2015).

Several patients with metastatic bone tumors are associated with bone-related adverse events, such as pathological fractures, pain, spinal cord compression, spinal instability, and hypercalcemia (Xu et al., 2016; Yang et al., 2019). Once NPC develops to bone metastases, the clinical stage is elevated from M0 to M1, and this change may significantly influence the adjustment of treatment strategies and patient prognosis. Consequently, the originally planned radiotherapy-based treatment strategy may be adjusted to the combination of chemotherapy-based treatment strategies (Chen et al., 2019). Therefore, early detection of patients with bone-metastatic NPC and determination of the site and number of bone metastases is crucial.

As a molecular imaging technique, positron emission tomography/computed tomography (PET/CT) can obtain metabolic information about malignant tumors (Ayati et al., 2021; Han and Choi, 2021). The $^{18}$F-NaF has been used for 40 years as an oleophilic contrast agent and is a positron imaging agent mainly for bone imaging, and its application was somewhat limited before the advent of PET/CT. Besides, the $^{18}$F-NaF has better pharmacokinetic properties than the contrast agent $^{99m}$Tc-MDP for bone imaging, and with the development of PET/CT, $^{18}$F-NaF has gradually attracted radiologists' attention (Grant et al., 2008; Segall et al., 2010). In 2015, the European Society of Nuclear Medicine issued guidelines for the clinical application of $^{18}$F-NaF PET/CT for bone imaging successively (Beheshti et al., 2015).$^{18}$F-NaF PET/CT imaging of various malignant tumors, such as prostate cancer (Langsteger et al., 2016), breast cancer (Arvola et al., 2019), and lung cancer (Rao et al., 2016) has been conducted, which showed its potential application value. We have previously investigated the Observer agreement and accuracy of $^{18}$F-NaF PET/CT in the diagnosis of bone metastases in NPC (Xiao et al., 2020). However, only a few studies with a small sample size have concentrated on $^{18}$F-NaF PET/CT imaging of NPC (Zhang et al., 2018), and no quantitative study has been carried out. Thus, the present study aimed to investigate the diagnostic value of $^{18}$F-NaF PET/CT in the diagnosis of bone metastases in patients with NPC using visual and quantitative analyses in large samples. We hypothesized that $^{18}$F-NaF PET/CT has high diagnostic efficacy in diagnosing bone metastases and that SUVmax is valuable in differentiating bone metastases from benign bone lesions in NPC.

Materials and methods

Patients

We retrospectively reviewed the images of NPC patients who underwent $^{18}$F-NaF PET/CT in our center from 1 July 2017 and 31 June 2021. The inclusion criteria were as follows: i. Patients who were histopathology confirmed with NPC; ii. Performing whole-body $^{18}$F-NaF PET/CT before NPC therapy; iii. Availability of standardized treatment and clinical and imaging follow-up data for more than half a year, including CT, magnetic resonance imaging (MRI), and PET/CT findings; iv. Patients without other serious complications or other types of cancer. A total of 164 patients were enrolled. The study included 124 men and 40 women aged 21 to 71 (average age, 51.2) years old. Patients were staged according to the 8th edition of the American Joint Committee on Cancer (AJCC) TNM staging system. This retrospective study was approved by the Ethics Committee of Affiliated Hospital of Guangdong Medical University. A flow diagram summarizing the initial candidates and each exclusion procedure are shown in Figure 1.
18F-NaF PET/CT

18F-NaF PET/CT was conducted in accordance with the guidelines from the Nuclear Medicine and the European Association of Nuclear Medicine. Patients received an intravenous injection of approximately 200 MBq of 18F-NaF. The PET data were acquired at 64±6 (mean ± standard deviation (SD) min after the tracer injection using the GE Discovery Elite 690 PET/CT scanner (General Electric Medical Systems, Milwaukee, WI, United States). Low-dose helical CT transmission scan was carried out (pitch, 0.984, current, 120–230 mAs; voltage, 120 kV; display field of view (DFOV), 50.0 cm; slice thickness, 3.75 mm; reconstruction slice, 1.25 mm). The static emission scan was performed over the whole body with 2-min (the GE Discovery-690 PET/CT scanner) acquisition times per bed position. The sinogram data of CT were corrected for dead time, decay, and photon attenuation and reconstructed in a 128×128 matrix. Image reconstruction followed a fully three-dimensional (3D) maximum likelihood ordered subset expectation-maximization algorithm.

Definition of bone metastases and benign bone lesions

Bone Metastases: the areas of focally increased 18F-NaF uptake were recorded as malignant unless a benign etiology (e.g., degenerative changes or hemangioma) for this uptake was identified at the same location on the corresponding CT images. The CT component of PET/CT was used to determine whether bone lesions identified on PET had an osteoblastic or osteolytic appearance. Bone destruction or osteoblastic manifestation of bone (local and asymmetric lesions with increased density) with NaF uptake was targeted as malignancy. Bone metastases are classified into four types: osteolytic, osteogenic, mixed and without significant changes based on CT images.

Benign bone lesions: localized abnormally concentrated radioactive lesions with a history of trauma, surgery, radiation therapy, etc., and typical fractures, osteophytes and benign bone tumors on CT defined as benign bone lesions. Osteomalacia/degeneration was defined as intervertebral disc degeneration in the form of vacuum sign, labral hyperplasia and sclerosis at the margins of the vertebral body; hyperplasia and sclerosis of the intervertebral small joint and sacroiliac joint surfaces. Fracture is defined as disruption of cortical continuity, or multiple fragmented fracture fragments, displacement of the fracture may also be seen, and bone repair/scab formation after follow-up.

Reference standard

The reference standard followed Jadvar et al.’s research method (Jadvar et al., 2012). The final bone metastasis of a given site was determined based on either pathological examination from CT-guided or surgical biopsies or the results of follow-up by MRI, contrast-enhanced CT or PET/CT for more than 6 months for every patient. The suspicious lesions detected by PET/CT were confirmed to be metastasis when the tissues were pathologically proved to be metastatic, or the lesions became larger during the follow-up periods or decreased in size after treatment. On the contrary, they were diagnosed as non-metastatic lesions when no change in size was observed during follow-up examinations. The final diagnosis was arrived at by consensus at a conference held by the multidisciplinary group of NPC in our hospital.

| Characteristics                          | (n = 164) |
|------------------------------------------|-----------|
| Gender                                   |           |
| Male                                     | 124       |
| Female                                   | 40        |
| Age (Mean ± standard deviation)          | 50.132±11.95 |
| Pathological typing                      |           |
| Undifferentiated non-keratinizing carcinoma | 160     |
| Differentiated non-keratinizing carcinoma | 4        |
| M-staging                                |           |
| M0                                       | 128       |
| M1                                       | 36        |
| TNM staging                              |           |
| I                                        | 0         |
| II                                       | 14        |
| III                                      | 70        |
| IVa                                      | 44        |
| IVb                                      | 36        |
| Bone metastasis area (site)              | 444       |
| Ribs                                     | 94        |
| Pelvic bone                              | 93        |
| Cervical Spine                           | 30        |
| Thoracic spine                           | 85        |
| Lumbar spine                             | 55        |
| Scapula                                  | 32        |
| Limb bone                                | 26        |
| Skull                                    | 13        |
| Others                                   | 16        |
**Statistical analysis**

All data were analyzed based on two levels, including the lesion level and the patient level. Indicators of diagnostic performance were expressed using dichotomous variables. Diagnostic performance was evaluated using positive-predictive value (PPV), negative-predictive value (NPV), sensitivity, specificity, and accuracy.

Quantitative data were expressed as mean ± SD; multiple continuous variables were compared using one-way analysis of variance (ANOVA), and multiple comparisons among more than two groups were made using the Bonferroni method; a standardized uptake value (SUV) threshold was proposed to be used as a cut-off for diagnosing metastatic bone lesions versus benign bone lesions (non-osteophytes, non-fractures, etc.). Using receiver operating characteristic (ROC) curves. The statistical analysis was performed using R (version. 3.6.3; www.r-project.org) software, and $p < 0.05$ was considered statistically significant.

**Results**

**Patients’ clinical characteristics**

A total of 164 patients were included in the analysis. Thirty-five (21.3%) patients with NPC developed bone metastases, with 444 metastatic bone lesions and 281 benign bone lesions. The most common sites of metastatic osseous lesions were ribs ($n = 94$), followed by pelvic bones ($n = 93$). Patients’ clinical characteristics are summarized in Table 1.

**Visual evaluation of $^{18}$F-NaF PET/CT images**

Each patient’s $^{18}$F-NaF PET/CT images were independently interpreted by two board-certified nuclear medicine physicians. Both physicians (with experience in interpreting more than 1000 $^{18}$F-NaF PET/CT images) were blinded to the objectives of the study. If there was a discrepancy between the two readers, the opinion of a third expert with more than 10 years of nuclear medicine certification was included, and ultimately to judge the nature of the lesion by the vote of the three experts.

**Quantitative evaluation of $^{18}$F-NaF PET/CT imaging**

A total of 164 patients with 725 bone lesions were divided into metastatic bone lesion group ($n = 444$, defined as group 1) and benign lesion group ($n = 281$, defined as group 2); benign lesion group was further subdivided into benign lesion without osteophyte and fracture group (CT images showing no osteophyte, no fracture, defined as group 2.1), and benign lesion with osteophyte and fracture group (CT images showing typical osteophytes and fractures, e.g. the lesion is around the vertebral body, or a distinct fracture line is visible, defined as group 2.2), and the number of bone lesions in each group is presented in Table 3. Table 4 shows the results of a two-by-two comparison of SUVmax in each group. The results showed that there was no statistically significant difference between groups 1 and 2.2 (group 1 vs group 2.2, $p = 0.268$); between each pair of the remaining groups, significant differences were found (group 1 vs group 2, $p < 0.001$) (group 1 vs group 2.1, $p < 0.001$) (group 2 vs group 2.1, $p < 0.001$) (group 2 vs group 2.2, $p < 0.001$) (group 2.1 vs groups 2.2, $p < 0.001$). The box plots of the distribution of SUVmax of bone lesions in the four groups are shown in Figure 2.

The ROC curves of group 1 and group 2.1 are illustrated in Figure 3. It was revealed that the values of area under the curve (AUC), sensitivity, specificity, and the diagnostic cut-off value of SUVmax were 0.865 (95% CI: 0.831–0.899), 0.912, 0.656, and 12.5 g/ml, respectively (Table 5).

The metastatic bone lesions were differentiated according to their size, including 277 lesions with a diameter of ≥2 cm and 167 lesions with a diameter of <2 cm. The mean values of SUVmax of lesions in the two groups were 25.77±9.41 g/ml (≥2 cm group), and 16.35±5.75 g/ml (<2 cm group), respectively; the SUVmax of the lesion diameter ≥2 cm group was significantly higher than that of the lesion diameter <2 cm.
The metastatic bone lesions were differentiated according to their pattern according to CT findings, including 231 osteolytic lesions, 91 osteogenic lesions, and 122 lesions with no obvious changes on CT. The mean values of SUVmax of lesions in the three groups were 17.03±5.22 g/ml (osteolytic lesions), 29.27±10.12 g/ml (osteogenic lesions), and 26.82 ± 8.10 g/ml (no obvious changes in CT), respectively; the SUVmax of the osteogenic lesions group and lesions with no obvious changes on CT group were significantly higher than that of the osteolytic lesions group (t = -11.66, p < 0.01).

**Discussion**

Based on visual analysis, this study demonstrated that $^{18}$F-NaF PET/CT has excellent diagnostic accuracy in diagnosing bone metastases in patients with NPC. 35 (21.3%)
patients with NPC developed bone metastases, the most common site of bone metastasis was the rib cage, followed by the pelvis. In addition, this study revealed that quantitative NaF PET/CT is valuable in diagnosing bone metastases from NPC. To the best of our knowledge, this study was the first to perform a quantitative analysis of 18F-NaF PET/CT findings for the diagnosis of bone metastases in patients with NPC.

In this study, the sensitivities were 97.1% and 99.5% at the patient level and at the lesion level using visual analysis, respectively. A Meta-analysis (Shen C. T et al., 2015) demonstrated that the sensitivity of 18F-NaF PET/CT for the diagnosis of bone metastases in various cancer was 92% at the patient level and 87% at the lesion level. Zhang et al. (Zhang et al., 2018) found that the sensitivity of 18F-NaF PET/CT for detection of bone metastasis in 45 NPC patients was 98.3%, which was in line with our findings. The reasons for this high sensitivity are as follows. Firstly, 18F-NaF is an excellent radiopharmaceutical for bone imaging because fluoride ions are an analogue of the hydroxyl group found in the hydroxyapatite bone crystals, which exchange with hydroxyl groups in hydroxyapatite bone crystals to form fluorapatite (Grant et al., 2008). Secondly, it detects the presence of lesions directly by bone mineral metabolism rather than indirectly showing lesion involvement owing to the increased bone mineral turnover, especially in lesions with pathologic changes (Even-Sapir et al., 2004; Iagaru et al., 2013).

In addition to high sensitivity, our study also showed a noticeable specificity of 18F-NaF PET/CT, which was 94.6% at the patient level and 91.5% at the lesion level, and was close to the results of previous studies (Shen C. T et al., 2015; Zhang et al., 2018; Liu et al., 2019), mainly relying on the exclusion of benign lesions (e.g. fractures and osteophytes, from CT images). PET has been proved to be an effective tool in the management of malignant tumor patients, and it provides limited information on bone lesion morphologic abnormalities. Differentiation between benign lesions and malignant bone lesions is obtained by further CT validation (Figure 4). The remarkable nuclear medicine technological developments in positron imaging devices combined with coregistration CT have resulted in a renewed interest in 18F-NaF. Thus, 18F-NaF PET/CT detection can provide precise information regarding both the morphologic and bone mineral metabolism changes occurring in bone metastases, so the specificity of 18F-NaF PET in bone metastases detection can be improved by the use of the PET-CT system (Hawkins et al., 1992; Even-Sapir et al., 2004; Grant et al., 2008; Rao et al., 2016). However, as 18F-NaF is a non-bone metastasis-specific imaging agent, there were a few misdiagnoses that occurred in our study, including seven patients with false-positive test results with a false-positive rate of 5.4% (7/129) and 26 false-positive lesions with a false-positive rate of 9.25%. The reason for these results may be that some benign bone lesions do not have a high degree of NaF tracer uptake (only mildly increased uptake), and CT images do not show typical features of benign lesions (e.g., no osteophyte, no fracture, or degenerative changes), and there is an overlap between such lesions and bone metastases in terms of CT findings and PET of bone metabolism. Hence, Nuclear medicine physicians need to be cautious in drawing conclusions about metastatic bone lesions when a bone lesion is atypical in 18F-NaF PET/CT finding, in which further examination or a longer follow-up may be required.

Quantitative analysis has the advantage of higher objectivity and reproducibility than visual qualitative analysis, and it has been widely used in the F-fluorodeoxyglucose (18F-FDG) PET/CT (Boellaard, 2009). Compared with the 18F-FDG PET/CT, 18F-NaF PET/CT is more advantageous for diagnosing bone metastases due to its higher sensitivity and specificity (Iagaru et al., 2013; Zhang et al., 2018). It has been suggested that quantitative analysis of 18F-NaF PET/CT findings could indicate a small coefficient of variation and good

| Characteristic | Value       |
|---------------|-------------|
| Cutoff point  | 12.500      |
| Sensitivity   | 0.912       |
| Specificity   | 0.656       |
| AUC           | 0.865       |
| 95% CI of AUC | (0.831, 0.899) |
reproducibility, which could be used as a clinical reference for patient management (Sabbah et al., 2015; Lin et al., 2016). In addition, some scholars have quantitatively analyzed $^{18}$F-NaF PET/CT findings (SUVmax, SUVpeak) for the diagnosis of prostate cancer and other metastatic bone tumors, and evaluation of its efficacy after treatment revealed its potential application (Sabbah et al., 2015; Harmon et al., 2017; Muzi et al., 2021). Zhang et al. (Zhang et al., 2021) performed a quantitative single-photon emission computed tomography (SPECT)/CT-based study on 51 patients with malignant tumors, including 48 bone metastases and 40 benign bone lesions, and the results showed that the SUVmax of bone metastases (24.8 ± 16.3 g/ml) was significantly higher than that of benign lesions (15.9 ± 8.5 g/ml). The quantitative analysis of $^{18}$F-NaF PET/CT and $^{99m}$Tc-HDP SPECT/CT findings showed some similarities. In a study on the quantitative analysis of $^{18}$F-NaF PET/CT and $^{99m}$Tc-HDP SPECT/CT findings for detection of bone lesions at the same site in patients with prostate cancer and breast cancer, the SUVmax, SUVmean, SUVpeak, and SUV ratio of lesions to adjacent normal bone tissue were compared, and a strong positive correlation was found among the SUVs (SUVmax, SUVpeak, and SUVmean) ($R^2 \geq 0.80$) (Arvola et al., 2019). The results of the present study showed that the SUVmax of malignant bone lesions (22.2 ± 9.4) was significantly higher than that of benign bone lesions (17.5 ± 14.9), especially non-fractured and non-osteophytes lesions (11.7 ± 5.4) (Figure 5). In addition, we found a higher SUVmax in benign bone lesions with osteophytes and fractures, which was not significantly different from the bone metastasis group ($p = 0.268$). In clinical practice, CT images from the PET/CT machine can well identify typical benign bone lesions, such as fractures, and osteophytes lesions, while there is a diagnostic challenge in the identification of malignant bone lesions and benign bone lesions, which are non-osteophytes and non-fractures, accompanied by the increased $^{18}$F-NaF uptake. Therefore, the advantage of SUVmax in distinguishing metastatic bone lesions from benign bone lesions (non-osteophytes, non-fractures) includes an effective complement to the discrimination of CT images. According to the ROC curves for groups 1 and 2, found that the diagnostic sensitivity (91.2%) was higher with SUVmax ≥12.5 as the threshold, and this result may provide a reliable reference for clinical practice (Figure 6).

The difference in SUVmax between different sizes of bone metastases in NPC based on $^{18}$F-NaF PET/CT has not been previously reported. The present study showed statistically significant differences in SUVmax between metastatic bone lesions of different sizes. The SUVmax of lesions in the diameter ≥2 cm group was significantly higher than that in
FIGURE 5
Nasopharyngeal carcinoma (T3N2M1) in a 55-year-old male patient. Whole-body PET MIP (A) shows multiple abnormally $^{18}$F-NaF uptake in multiple ribs, the right sacroiliac joint, and the left clavicle; the SUVmax of the confirmed bone metastases in the left clavicle (B). PET/CT fusion, arrows and the left 8th posterior rib (C). PET/CT fusion, arrows is significantly higher than that in the right rib (D,E), arrows and the left clavicle (F,G), arrows for benign lesions (non-fracture, non-osteophytes).

FIGURE 6
Nasopharyngeal carcinoma (T2N2M0) in a 56-year-old male patient. The whole-body PET MIP image (A), arrow shows a focal mild abnormal $^{18}$F-NaF uptake in the right scapula, CT (B), small arrow shows a small sclerotic border, PET/CT image (C) shows a localized $^{18}$F-NaF uptake, and measurement of the lesion with SUVmax = 10.5. The lesion was first considered benign based on the CT findings and the degree of metabolism. A follow-up PET/CT (D), arrow at 1 year showed no metabolic changes and thus confirming the benign nature.
the diameter <2 cm group, suggesting that SUVmax may be influenced by the size of lesions. The possible mechanism is that larger lesions contain more tumor cells, which release more relevant cytokines resulting in faster bone blood flow and bone ion exchange, thereby requiring more imaging agents, accompanied by a larger SUVmax; on the other hand, small lesions are affected by partial volume effects, which may also lead to underestimation of SUVmax. In addition, the difference in SUVmax between different patterns of bone metastases in NPC based on 18F-NaF PET/CT has also not been previously reported. We found that osteogenic bone metastases had significantly higher SUVmax values than osteolytic metastases. The main principle is that the bone structure of osteogenic bone metastases has more and denser calcium deposits than the original bone structure, the blood exchange of bone salts is accelerated, and more 18F-NaF imaging agent is taken up; whereas, in osteolytic bone metastases, the bone structure is destroyed, the calcium salts are reduced, the bone density is decreased, and the blood exchange of bone salts is slowed, so the NaF uptake is reduced. In summary, after excluding osteophytes and fracture lesions based on CT findings, quantitative analysis of 18F-NaF PET/CT (SUVmax) can assist nuclear medicine physicians in the discrimination of metastatic bone lesions from benign bone lesions. Using SUVmax ≥12.5 as the threshold can be a valuable reference for identifying bone metastases in NPC. The size of a metastatic bone lesion may affect SUVmax. This study has limitations. Although it is a PET/CT study of NPC in a large sample, however, it is a retrospective study and bias exists. Second, a histological sampling of all detected metastases is usually not required for determining the oncologic treatment concept (Bruckmann et al., 2021). Therefore, the reference standard was also based on follow-up examinations using CT, MRI and PET/CT.

**Conclusion**

Visual analysis of 18F-NaF PET/CT findings is accompanied by high sensitivity and specificity for the diagnosis of bone metastases in NPC. Quantitative analysis of PET/CT (SUVmax) is valuable for the differential diagnosis of bone metastases in NPC. After excluding osteophytes and fracture lesions based on CT findings, using SUVmax ≥12.5 as the threshold can be an important reference for the differential diagnosis of bone metastases and benign bone lesions in patients with NPC. The next a multicenter prospective study is needed.

**Data availability statement**

The raw data supporting the conclusion of this article will be made available by the authors, without undue reservation.

**Ethics statement**

The studies involving human participants were reviewed and approved by the Affiliated Hospital of Guangdong Medical University Ethics Committee. Written informed consent to participate in this study.

**Author contributions**

HL and JX designed the study; DW and CG reviewed all the images, obtained the data, designed the statistical analysis, and finished the interpretation of the patient cohort; SH, CG, HL and XG. recruited the patients and provided the clinical data; JX wrote the manuscript; DW revised the manuscript. All authors have read and agreed to the published version of the manuscript.

**Funding**

This study was funded by the Guangdong Basic and Applied Basic Research Fund Enterprise Joint Fund in 2021 (No. 2021A1515220052), Guangdong Medical Research Fund Project (No. A2021116), Zhanjiang Science and Technology Projects (No. 2021A05054), and The Youth Research Fund of Guangdong Medical University (No. GDMUQ2021007).

**Acknowledgments**

The authors thank the entire nuclear medicine staff for their dedication.

**Conflict of interest**

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

**Publisher’s note**

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
References

Arvola, S., Jambor, I., Kuusma, A., Kemppainen, J., Kajander, S., Seppänen, M., et al. (2019). Comparison of standardized uptake values between (99m)Tc-HDP SPECT/CT and (18)F-NaF PET/CT in bone metastases of breast and prostate cancer. JNM 60, 9. doi:10.1186/s13550-019-0475-7

Ayati, N., Sadeghi, R., Kiamanesh, Z., Lee, S. T., Zakavi, S. R., and Scott, A. M. (2021). The value of (18)F-FDG PET/CT for predicting or monitoring immunotherapy response in patients with metastatic melanoma: a systematic review and meta-analysis. Eur J Nucl Med Mol Imaging 48, 428–448. doi:10.1007/s00259-020-04967-9

Beheshti, M., Mottaghy, F. M., Payne, F., Behrendt, F. F. F., Van den Wyngaert, T., Fogelman, I., et al. (2015). 18F-NaF PET/CT: EANM procedure guidelines for bone imaging. Eur J Nucl Med Mol Imaging 42, 1767–1777. doi:10.1007/s00259-015-3138-y

Boellaard, R. (2009). Standards for PET image acquisition and quantitative data analysis. J Nucl Med 50, 11s–20s. doi:10.2967/jnumed.108.057182

Bruckmann, N. M., Kirchner, J., Unutlu, L., Fendler, W. P., Seifert, R., Herrmann, K., et al. (2021). Prospective comparison of the diagnostic accuracy of 18F-FDG PET/MRI, MRI, CT, and bone scintigraphy for the detection of bone metastases in the initial staging of primary breast cancer patients. Eur Radiol 31, 8714–8724. doi:10.1007/s00330-021-09756-0

Chen, Y. P., Chan, A. T. C., Le, Q. T., Blanchard, P., Sun, Y., and Ma, J. (2019). Nasopharyngeal carcinoma. Lancet 394, 64–80. doi:10.1016/s0140-6736(19)30956-9

Even-Sapir, E., Metser, U., Flusser, G., Zuriel, L., Kollender, Y., Lerman, H., et al. (2004). Assessment of malignant skeletal disease: initial experience with 18F-fluoride PET/CT and comparison between 18F-fluoride PET and 18F-fluoride PET/CT. J Nucl Med 45, 272–278.

Grant, F. D., Fahy, F. H., Packard, A. B., Davis, R. T., Alvi, A., and Treves, S. T. (2008). Skeletal PET with 18F-fluoride: applying new technology to an old tracer. J Nucl Med 49, 68–78. doi:10.2967/jnumed.106.037200

Han, S., and Choi, J. Y. (2021). Impact of 18F-FDG PET/CT, PET/CT, and PET/MRI staging and management as an initial staging modality in breast cancer: A systematic review and meta-analysis. Clin Nucl Med 46, 271–282. doi:10.1097/RLU.0000000000001311

Harmon, S. A., Perk, T., Lin, C., Eickhoff, J., Choyke, P. L., Dahut, W. L., et al. (2017). Quantitative assessment of early [(18)F]sodium fluoride positron emission tomography/computed tomography response to treatment in men with metastatic prostate cancer to bone. J Clin Oncol 35, 2829–2837. doi:10.1200/jco.2017.72.2348

Hawkins, R. A., Choi, Y., Huang, S. C., Hol, C. K., Dahlborn, M., Schepers, C., et al. (1992). Evaluation of the skeletal kinetics of fluorine-18 fluoride ion with PET. J Nucl Med 33, 631–642.

Iagaru, A., Young, P., Mittra, E., Dick, D. W., Herfkens, R., and Gambhir, S. S. (2013). Pilot prospective evaluation of 99mTc-HDP emission tomography/computed tomography response to treatment in men with metastatic prostate cancer to bone. J Nucl Med 54, 282–289. doi:10.2967/jnumed.112.124326

Jadvar, H., Desai, B., Conti, P. S., Dorff, T. B., Groshen, S. G., et al. (2012). Prospective evaluation of 18F-NaF and 18F-FDG PET/CT in detection of occult metastatic disease in biochemical recurrence of prostate cancer. Clin Nucl Med 37, 637–643. doi:10.1097/RLU.0b013e18252d82b9

Langsteger, W., Rezaee, A., Pirch, C., and Beheshti, M. (2016). (18F-Fluoride PET/CT and (99m)Tc-MDP bone scintigraphy in the detection of bone metastases in prostate cancer. Semin Nucl Med 46, 491–501. doi:10.1016/j.semnulmed.2016.07.003

Lin, C., Bradshaw, T., Perk, T., Harroon, S., Eickhoff, J., Jallow, N., et al. (2016). Repeatability of quantitative 18F-FDG PET: A multicenter study. J Nucl Med 57, 1872–1879. doi:10.2967/jnumed.116.177295

Liu, Y., Sheng, J., Dong, Z., Xu, Y., Huang, Q., Pan, D., et al. (2019). The diagnostic performance of 18F-fluoride PET/CT in bone metastases detection: a meta-analysis. Clin Radiol 74, 196–206. doi:10.1016/j.crad.2018.12.011

Muzi, M., O’Sullivan, F., Perk, T. G., Muzi, J. P., Mankoff, D. A., Jeraj, R., et al. (2021). Whole-body [(18)F]-Fluoride PET SUV imaging to monitor response to dasatinib therapy in castration-resistant prostate cancer bone metastases: Secondary results from ACRIN 6687. Tomography 7, 139–152. doi:10.3390/ tomography7020013

Rao, L., Zong, Z., Chen, Z., Wang, X., Shi, X., Yi, C., et al. (2016). 18F-Labeled NaF PET/CT in detection of bone metastases in patients with preoperative lung cancer. Med. Baltim. 95, e3490. doi:10.1097/md.0000000000004390

Sabbah, N., Jackson, T., Mosci, C., Jamali, M., Minamimoto, R., Quon, A., et al. (2015). 18F-sodium fluoride PET/CT in oncology: an atlas of SUVs. Clin Nucl Med 40, e228–231. doi:10.1097/RLU.0000000000000633

Segall, G., Debeke, D., Stabin, M. G., Even-Sapir, E., Fair, J., Sajdak, R., et al. (2010). SNM practice guideline for sodium 18F-fluoride PET/CT bone scans i.0. J Nucl Med 51, 1813–1820. doi:10.2967/jnumed.110.082263

Shen, C. T., Qiu, Z. L., Han, T. T., and Lao, Q. Y. (2015). Performance of 18F-fluoride PET or PET/CT for the detection of bone metastases: a meta-analysis. Clin Nucl Med 40, 103–110. doi:10.1097/RLU.0000000000000592

Shen, L. I., Wang, S. Y., Xie, G. F., Zeng, Q., Chen, C., Dong, A. N., et al. (2015). Subdivision of M category for nasopharyngeal carcinoma with synchronous metastasis: time to expand the M categorization system. Chin J Cancer 34, 40–458. doi:10.4068/cjca20150101.0010391

Xiao, J., Wang, D., Guo, B., Wang, L., Su, M., and Xu, H. (2020). Observer agreement and accuracy of 18F-sodium fluoride PET/computed tomography in the diagnosis of skull-base bone invasion and osseous metastases in newly diagnosed nasopharyngeal carcinoma. Nucl Med Commun 41, 942–949. doi:10.1097/mnm.0000000000001243

Xu, J. Y., Murphy, W. A., Jr., Milton, D. R., Jimenez, C., Rao, S. N., Habra, M. A., et al. (2016). Bone metastases and skeletal-related events in medullary thyroid carcinoma. J Nucl Med 57, 151–157. doi:10.2967/jnumed.115.177269

Yang, M., Liu, C., and Xu, Y. (2019). Skeletal-related adverse events during bone metastasis of breast cancer: current status. Discov Med. 27, 211–220

Zhang, Y., Chen, Y., Huang, Z., Zhang, L., Wan, Q., and Lei, L. (2018). Comparison of (18)F-NaF PET/CT and (18)F-FDG PET/CT for detection of skull-base invasion and osseous metastases in nasopharyngeal carcinoma. Contrast Media Mol Imaging 2018, 8271313. doi:10.1155/2018/8271313

Zhang, Y., Li, B., Yu, H., Song, J., Zhou, Y., and Shi, H. (2021). The value of skeletal standardized uptake values obtained by quantitative single-photon emission computed tomography-computed tomography in differential diagnosis of bone metastases. Nucl Med Commun 42, 63–67. doi:10.1097/mnm.0000000000001311